Jonathan D Cheng

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens
    Jiping Zhang
    1Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    FASEB J 27:581-9. 2013
  2. ncbi Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model
    Jonathan D Cheng
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 62:4767-72. 2002
  3. ncbi Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth
    Jonathan D Cheng
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Mol Cancer Ther 4:351-60. 2005
  4. ncbi Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647
    Jonathan D Cheng
    Fox Chase Cancer Center, Department of Medical Oncology, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 9:1590-5. 2003
  5. ncbi Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Jeanes Hospital, Philadelphia, PA 19111 2497, USA
    Pancreas 37:154-8. 2008
  6. ncbi Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma
    Igor A Astsaturov
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 34:70-5. 2011
  7. ncbi Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma
    Andre A Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 69:358-63. 2007
  8. ncbi Clinical implications of fibroblast activation protein in patients with colon cancer
    Leonard R Henry
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Clin Cancer Res 13:1736-41. 2007
  9. ncbi FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells
    Hyung Ok Lee
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA
    BMC Cancer 11:245. 2011
  10. ncbi Resection of isolated pelvic recurrences after colorectal surgery: long-term results and predictors of improved clinical outcome
    Leonard R Henry
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Ann Surg Oncol 14:2000-9. 2007

Collaborators

Detail Information

Publications24

  1. ncbi Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens
    Jiping Zhang
    1Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    FASEB J 27:581-9. 2013
    ..Robinson, M. K., Lee, H.-O., Mullins, S. R., Marasco, W. A., Adams, G. P., Weiner, L. M., Cheng, J. D. Identification of inhibitory ScFv antibodies targeting fibroblast activation protein utilizing phage display functional screens...
  2. ncbi Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model
    Jonathan D Cheng
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 62:4767-72. 2002
    ..Moreover, tumor growth is attenuated by antibodies that inhibit the proteolytic activity of FAP. These findings suggest a possible therapeutic role for functional inhibition of FAP activity...
  3. ncbi Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth
    Jonathan D Cheng
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Mol Cancer Ther 4:351-60. 2005
    ....
  4. ncbi Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647
    Jonathan D Cheng
    Fox Chase Cancer Center, Department of Medical Oncology, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 9:1590-5. 2003
  5. ncbi Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Jeanes Hospital, Philadelphia, PA 19111 2497, USA
    Pancreas 37:154-8. 2008
    ....
  6. ncbi Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma
    Igor A Astsaturov
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 34:70-5. 2011
    ..We evaluated the role of the anti-vascular endothelial growth factor antibody bevacizumab as second-line treatment for patients with metastatic pancreatic cancer...
  7. ncbi Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma
    Andre A Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 69:358-63. 2007
    ....
  8. ncbi Clinical implications of fibroblast activation protein in patients with colon cancer
    Leonard R Henry
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Clin Cancer Res 13:1736-41. 2007
    ..The primary objective of this study was to evaluate the clinical significance of stromal FAP in human colon cancers by immunohistochemisty...
  9. ncbi FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells
    Hyung Ok Lee
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA
    BMC Cancer 11:245. 2011
    ..We tested the hypothesis that FAP enzymatic activity locally modifies stromal ECM (extracellular matrix) components thus facilitating the formation of a permissive microenvironment promoting tumor invasion in human pancreatic cancer...
  10. ncbi Resection of isolated pelvic recurrences after colorectal surgery: long-term results and predictors of improved clinical outcome
    Leonard R Henry
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Ann Surg Oncol 14:2000-9. 2007
    ..Resection offers the only reasonable probability for cure, but at the cost of perioperative morbidity and potential mortality. Clinical decision making remains difficult...
  11. ncbi Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report
    Leonard R Henry
    Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA
    Ann Surg Oncol 13:214-20. 2006
    ..The incorporation of taxanes into induction strategies for esophageal cancer seems promising, but the optimal schedule remains undefined...
  12. ncbi Morbidity and mortality are not increased after induction chemoradiotherapy followed by esophagectomy in patients with esophageal cancer
    Adam C Berger
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Semin Oncol 32:S16-20. 2005
    ..5 days). Esophagectomy can be performed safely with low mortality and acceptable morbidity following neoadjuvant chemotherapy and radiation with no increase in hospital stay for patients with complications...
  13. ncbi Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer
    Kalyani Narra
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1691-9. 2007
    ..The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic colorectal cancer...
  14. ncbi Resection of isolated pelvic recurrences after colorectal surgery: long-term results and predictors of improved clinical outcome
    Leonard R Henry
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Ann Surg Oncol 14:1081-91. 2007
    ..Resection offers the only reasonable probability for cure, but at the cost of marked perioperative morbidity and potential mortality. Clinical decision making remains difficult...
  15. ncbi Identification and characterization of the promoter of fibroblast activation protein
    Jiping Zhang
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Front Biosci (Elite Ed) 2:1154-63. 2010
    ..These findings identify the basal transcriptional requirements of FAP gene expression and show EGR1 is an important regulator of FAP expression...
  16. ncbi Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience
    Andre Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Oncol 32:S63-7. 2005
    ..Because response to preoperative treatment predicts clinical outcome, the utility of midtreatment PET scans to guide treatment decisions should be further explored in larger clinical studies...
  17. ncbi Evolution of tumor invasiveness: the adaptive tumor microenvironment landscape model
    Hyung Ok Lee
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia 19111, USA
    Cancer Res 71:6327-37. 2011
    ..Together, this work illustrates the partnership between evolutionary mathematical modeling and experimental validation as a potentially useful approach to study the complex dynamics of the tumor microenvironment...
  18. ncbi Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936
    Jonathan D Cheng
    Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 22:602-9. 2004
    ....
  19. ncbi Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Clin Colorectal Cancer 6:125-32. 2006
    ....
  20. ncbi Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival
    Adam C Berger
    Department of Surgical Oncology, and Division of Biostatistics, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 23:4330-7. 2005
    ..0001 and P <.0002, respectively). CONCLUSION: Response to CRT and the ability to perform an R0 resection are associated with significantly improved survival in patients with esophageal carcinoma...
  21. ncbi Selective fluorescence probes for dipeptidyl peptidase activity-fibroblast activation protein and dipeptidyl peptidase IV
    Koon Siew Lai
    Center of Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Bioconjug Chem 18:1246-50. 2007
    ..Furthermore, the novel probes can differentiate between FAP and DPP-IV proteolytic activities in cellular assay. Potentially, this assay platform is immediately useful for novel drug discovery...
  22. ncbi Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14
    K Kian Ang
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 97, Houston, TX 77030, USA
    J Clin Oncol 23:3008-15. 2005
    ..To investigate the feasibility of combining concomitant boost accelerated radiation regimen (AFX-C) with cisplatin and to assess its toxicity and the relapse pattern and survival in patients with advanced head and neck carcinoma (HNC)...
  23. ncbi Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14)
    Adam S Garden
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:1351-5. 2008
    ..This article reports the long-term toxicity, relapse patterns, and survival in patients with advanced head and neck carcinoma...
  24. ncbi Dipeptidyl peptidase 8/9-like activity in human leukocytes
    Marie Berthe Maes
    Laboratory of Medical Biochemistry, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
    J Leukoc Biol 81:1252-7. 2007
    ....